| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
4 companies
Samsara Biocapital Gp, LLC last filed a Form 4 in March 2025, as 10% Owner at SRRK. The filings on record cover 4 companies.
Historically, Samsara Biocapital Gp, LLC's trades have earned a middling insider score of 59/100 across 4 rated trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of +34.4%.
At the last filing, the largest reported position was 6,788,609 shares of SRRK. Net of sales, the SRRK filings show accumulation of 2,189,781 shares.
Samsara Biocapital Gp, LLC has 5 Form 4 filings on record from October 2023 to March 2025, across 4 companies: 10% Owner at Mineralys Therapeutics (MLYS), 2024–2025; 10% Owner at Neurogene (NGNE), 2024; 10% Owner at vTv Therapeutics (VTVT), 2024, and 1 more.
The 9 reported transactions were 7 open-market purchases, 1 other transaction and 1 option or other derivative award.
Counted by filing, the open-market trades come to 4 purchases worth about $31.9M and no sales.
The largest open-market purchase was 2,189,781 shares of SRRK at an average $6.85 on October 16, 2023, about $15.0M. Twelve months later SRRK was up 246%.
Shares as reported in the last Form 4 for each company; the most recent is from March 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 13, 2025 | MLYS Mineralys Therapeutics, Inc. | 10% Owner | Buy | 600,000 | $13.50 | $8,100,000.00 | +11.8% | +15.2% | +94.0% | |
| Nov 26, 2024 | NGNE Neurogene Inc. | 10% Owner | Buy | 48,770 | $25.83 | $1,259,622.58 | +2.9% | -38.2% | -21.9% | |
| Feb 12, 2024 | MLYS Mineralys Therapeutics, Inc. | 10% Owner | Buy | 555,555 | $13.50 | $7,499,992.50 | +12.3% | -12.2% | -34.4% | |
| Oct 16, 2023 | SRRK Scholar Rock Holding Corp | 10% Owner | Buy | 2,189,781 | $6.85 | $14,999,999.85 | +47.6% | +92.6% | +245.5% |